Profile
From: WHO, 2015. Cambodia Malaria Profile. Geneva: World Health Organization. Available at: www.who.int
Epidemiological profile of Cambodia
| Population by malaria endemicity (000) | 2015 | % |
|---|---|---|
| High transmission (≥ 1 case per 1000 population) | 7 500 | 48 |
| Low transmission (0-1 cases per 1000 population) | 3 520 | 23 |
| Malaria free (0 cases) | 4 560 | 29 |
| Total population | 15 580 |
| Parasites and vectors | |
|---|---|
| Major plasmodium species | P. falciparum (61%), P. vivax (39%) |
| Major anopheles species | An. minimus, dirus, maculatus, sundaicus |
Intervention policies and strategies
| Intervention | WHO-recommended policy/strategy | Yes/no | Year adopted |
|---|---|---|---|
| ITN/LLIN |
ITNs/LLINs distributed free of charge ITNs/LLINs distributed to all age groups |
Yes Yes |
2000 2000 |
| IRS |
IRS is recommended DDT is used for IRS |
Yes No |
- - |
| IPT | IPT is used to prevent malaria during pregnancy | N/A | |
| Case management |
Patients of all ages should receive diagnostic test RDTs used at community level ACT is free for all ages in public sector Pre-referral treatment with recommended medicines Oral artemisinin-based monotherapies are not registered |
Yes Yes Yes No Yes |
2000 2000 2000 - 2009 |
| Antimalarial policy | Type of medicine | Year adopted |
|---|---|---|
| First-line treatment of unconfirmed malaria | - | - |
| First-line treatment of P.falciparum | AS+MQ; DHA-PPQ+PQ | 2000 |
| For treatment failure of P.falciparum | QN+T | 2000 |
| Treatment of severe malaria | AM;AS; QN | - |
| Treatment of P.vivax | DHA-PPQ | 2011 |
Therapeutic efficacity tests (therapeutic or parasitological failure, %)
| Medicine | Year | No. of studies | Min. | Median | Max. | Follow-up | Species |
| AS+MQ | 2005-2016 | 17 | 0 | 1.4 | 19.4 | 42 days | P. falciparum |
| DHA-PPQ | 2008-2011 | 30 | 0 | 8.3 | 62.5 | 42 days | P. falciparum |
| DHA-PPQ | 2010-2016 | 8 | 0 | 0 | 3.3 | 28 days | P. vivax |
